(Q34187298)

31 July 2017

1 reference

title

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity (English)

1 reference

31 July 2017

1

Celestia S Higano

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

61

1 reference

31 July 2017

issue

2 Suppl 1

1 reference

31 July 2017

page(s)

32-38

1 reference

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Management of erectile dysfunction following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Hot flushes are induced by thermogenic stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Transdermal estrogen in the treatment of hot flushes in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Megestrol Acetate for the Prevention of Hot Flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Management of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Fatigue in patients with prostate cancer receiving hormone therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Fatigue and quality of life outcomes of exercise during cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902397-X

7 January 2021

10.1016/S0090-4295(02)02397-X

Identifiers

DOI

1 reference

31 July 2017

1 reference